Clinical Trial

Study to Assess Safety, Tolerability, PK, and PD of Multiple Doses of ZE63-0302 Administrated Orally in T2DM Patients.

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A Phase 1b study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple doses of ZE63-0302 administrated orally in T2DM patients.
Protocol Amendment History 3 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-12
notable Trial sites expanded: 5 -> 10 locations 2026-05-12
notable Primary completion moved earlier: 2026-08 -> 2026-04-21 2026-05-12
Trial Details
NCT Number NCT07234864
Lead Sponsor Eilean Therapeutics
Conditions Type 2 Diabetes
Enrollment 60 participants
Start Date 2025-11-19
Primary Completion 2026-04-21 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2026-05-11